Bicycle Therapeutics plc
BCYC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $2 |
| - Cash | $1 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 30.8% | 86.5% | 23.6% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -390.3% | -480.1% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -467.4% | -679.9% | -741.3% | -547.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -479.2% | -669.7% | -779.3% | -571.2% |
| EPS Diluted | -2.9 | -5.08 | -3.8 | -2.67 |
| % Growth | 42.9% | -33.7% | -42.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |